Fintel reports that on April 25, 2025, Wells Fargo downgraded their outlook for United Therapeutics (NasdaqGS:UTHR) from ...

In a report released today, Tiago Fauth from Wells Fargo downgraded United Therapeutics (UTHR – Research Report) to a Hold, with a price target ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $352.0, a high estimate of $425.00 ...

Wells Fargo downgraded United Therapeutics (UTHR) to Equal Weight from Overweight with a price target of $314, down from $395.Stay Ahead of the ...

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...

Wall Street expects a year-over-year increase in earnings on higher revenues when United Therapeutics (UTHR) reports results for the quarter ended March 2025. While this widely-known consensus outlook ...

It is worth considering United Therapeutics (UTHR), which belongs to the Zacks Medical - Drugs industry. This drugmaker has an established record of topping earnings estimates, especially when ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 21, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its ...

Wall Street expects a year-over-year increase in earnings on higher revenues when United Therapeutics (UTHR) reports results for the quarter ended March 2025. While this widely-known consensus ...